Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.22.4
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue:    
Contract Revenue $ 3,188 $ 33
Costs and Expenses:    
Research and development 16,678 14,583
General and administrative 11,100 10,185
Total costs and expenses 27,778 24,768
Loss from operations (24,590) (24,735)
Sale of New Jersey net operating loss & tax credits 3,491 1,328
Other income, net 102 124
Net loss (20,997) (23,283)
Preferred stock series B accumulated dividends (396)
Net loss attributable to common shareholders $ (20,997) $ (23,679)
Net loss attributable to common shareholders per share – basic and diluted $ (0.10) $ (0.11)
Weighted average common shares outstanding:    
Basic and diluted 216,811,439 210,178,332
Other comprehensive loss, net of tax    
Net unrealized loss on securities available-for-sale $ (679) $ (374)
Other comprehensive loss, net of tax (679) (374)
Comprehensive loss attributable to shareholders $ (21,676) $ (23,657)